About 5'-nucleotidase domain-containing protein 4
5'-nucleotidase domain-containing protein 4 (NT5DC4) is a protein
from Homo sapiens identified by UniProt accession
Q86YG4, 428 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | 5'-nucleotidase domain-containing protein 4 |
| UniProt accession | Q86YG4 |
| Gene | NT5DC4 |
| Organism | Homo sapiens |
| Length | 428 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- Filippi syndrome · score 0.37
- mean platelet volume · score 0.35
- platelet count · score 0.33
- matrix metalloproteinase 1 measurement · score 0.24
- neutrophil count · score 0.21
- gut microbiome measurement · score 0.20
- genetic disorder · score 0.19
- mean corpuscular volume · score 0.12
- leukocyte count · score 0.10
- birth measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86YG4-F1 | alphafold | PREDICTED | 86.96 | — |
Amino-acid sequence (428 residues)
MPAWIFVNRS LALGKIRCFG FDMDYTLAAY KSPAYEALTF ELLLERLVCI GYPHEILRYT YDPTFPTRRL VFDELYGNLL KVDAHGNVLL GAYGFTFLSE AEIWSFYPSK FIQRDDLQCF YILNMLFNLP ETYLYACLVD FFSGCSRYTN CDTGYQHGNL FMSFRSLFQD VTDAMNNIHQ SGCLKKTLED LEKYVKKDPR LPILLGKMKE VGKVFLATNS SYNYTNAIMT YLFSISEAEA SGRPWRSYFD LIVVDTQKPH FFAEGLVLRQ VNTDSGKLHV GTYTGPHQHC AVYSGGSSDM VCELLGVRGM DILYIGDHIF GDILKSKKRQ GWRTCLVVPE LSWELDIWAQ EKERLEELKR LDTHLADIYQ HMDGSSCELQ VINFTKREIQ MPHESVVEQE QANLDPASCL LSCNQRSLPA KSCLSSAI
Explore 5'-nucleotidase domain-containing protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets